ChinaDaily Briefs

China: AKM Industrial, Yashili International Holdings, Meituan, Akeso Biopharma Inc, Shangri-La Asia, JD.com Inc., Shimao Property Holdings and more

In today’s briefing:

  • AKM Industrial’s Offer Spread Risk/Reward
  • Merger Arb Mondays – Yashili, Razer, 51job, Sezzle, Link, Uniti, Guodian, Jin Jiang
  • Meituan (3690 HK): 4Q21, Strong Revenue and Promising Initiatives
  • Akeso Biopharma Inc (9926.HK) – Caution Is Advised Until Sufficient Financing Is Secured
  • Shangri-La Asia (69 HK): On a Clear Recovery Path
  • JD.com (9618) Re Test of Low Sets up a Very Bullish 2H 2022
  • Morning Views Asia: China Aoyuan Property, Guangzhou R&F Properties

AKM Industrial’s Offer Spread Risk/Reward

By Arun George

  • AKM Industrial (1639 HK)’s privatisation offer from Alpha Luck and AKM Meadville of HK$1.8345 consists of a base offer (HK$1.82) and a final dividend (HK1.45 cents). 
  • Approval from the State Administration of Foreign Exchange is the remaining pre-condition. The Court hearing of the petition for the sanction of the scheme is set for 19 July.
  • At last close and for a July end effective date, the gross and annualised spread to the total offer of HK$1.8345 is 3.6% and 11.2%, respectively.

Merger Arb Mondays – Yashili, Razer, 51job, Sezzle, Link, Uniti, Guodian, Jin Jiang

By Arun George


Meituan (3690 HK): 4Q21, Strong Revenue and Promising Initiatives

By Ming Lu

  • Meituan’s total revenue continued to rise strongly by 31% in 4Q21.
  • Initiatives businesses are losing money, but two of them are in leading positions.
  • We believe the stock has a 20% upside for this year.

Akeso Biopharma Inc (9926.HK) – Caution Is Advised Until Sufficient Financing Is Secured

By Xinyao (Criss) Wang

  • Akeso has a very high starting point, and was regarded as the leader of domestic second-tier biotech companies. However, in current unfavorable market sentiment, it’s necessary to re-examine the Company.
  • In Akeso’s pipeline, there are some valuable and differentiated candidates, especially in the field of bispecific antibodies. Its R&D capability is also well recognized.
  • However, due to the rich pipeline, related clinical trials will drain money fast. So, investors are advised to be cautious until Akeso has ensured sustainable and stable cash flow.

Shangri-La Asia (69 HK): On a Clear Recovery Path

By Osbert Tang, CFA

  • There is a strong recovery in Shangri-La Asia (69 HK) in 2H21 as its losses narrowed 36.4% HoH and by 57.5% YoY – hotels and investment properties are primary drivers.
  • 1Q22 momentum is solid with occupancy outside of Hong Kong and mainland China saw good YoY rebound. In FY21, room rates in France, Australia and UK have surpassed 2018 levels.
  • Refinancing for FY22 has almost completed, implying minimal liquidity risks. Trading at 76% discount to adjusted NAV of HK$25.44, the stock is way too cheap.

JD.com (9618) Re Test of Low Sets up a Very Bullish 2H 2022

By Thomas Schroeder

  • JD.com (9618) HK denotes formidable resistance  at 260 that will induce a downside re test toward the low zone. 
  • High sell volumes on the decline followed by weak buy volumes on the recent rise makes for a vulnerable rise with risk of a hard giveback.
  • Low re test/new low sets up a buy for a rally to 310/350 in Q3/Q4. Bullish macro A-B-C pullback sequence stands out.

Morning Views Asia: China Aoyuan Property, Guangzhou R&F Properties

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Before it’s here, it’s on Smartkarma